Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: GSK 10.595, CSL 3.6525.
* CSL reports semi-annually. Values are evenly split across both quarters within each half.
GSK vs CSL Net Worth and Market Cap
GSK (GSK) and CSL (CSL.AX) are peers in Vaccines. GSK reported revenue of $10.6B as of Q2 2026, compared with $7.3B for CSL. GSK leads on revenue.
GSK's gross margin is 73.0% versus 44.4% for CSL. GSK's net margin is 5.2% versus -40.2% for CSL.
Key differences
- Revenue growth from Q2 2025 to Q2 2026: GSK +5.3%, CSL +0.7%.
- CSL keeps more of its revenue as operating profit: a 19.0% operating margin, against 5.7% at GSK.
- GSK's KPIs on Sterling include Arexvy Sales by Region (Quarterly) and HIV Franchise Sales (Quarterly).
- CSL's KPIs on Sterling include Behring Revenue by Therapy (Annual) and Behring IVIG vs SCIG Revenue (Annual).
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, GSK, CSL.| Metric | GSK | CSL |
|---|---|---|
| Market Cap | - | - |
| Revenue | $10.60B | $7.30B |
| Cost of Revenue | $2.85B | $4.06B |
| Gross Profit | $7.74B | $3.24B |
| Operating Income | $606.00M | $1.39B |
| Net Income | $548.00M | $-2.94B |
| R&D Expense | $4.37B | $614.00M |
| Earnings Per Share | $0.28 | -$6.14 |
| Gross Margin | 73.0% | 44.4% |
| Operating Margin | 5.7% | 19.0% |
| Net Profit Margin | 5.2% | -40.2% |
| Free Cash Flow | $2.78B | $1.76B |
| Cumulative Free Cash Flow | $157.21B | $21.56B |
| Operating Cash Flow | $3.19B | $2.09B |
| Cash & Equivalents | $3.89B | $1.51B |